Diagnostic Histopathology
Volume 14, Issue 9 , Pages 437-452 , September 2008

Neoplastic precursor lesions of the upper gastrointestinal tract

References 

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  2. Ribeiro U, Posner MC, Safatle-Ribeiro AV, Reynolds JC. Risk factors for squamous cell carcinoma of the oesophagus. Br J Surg. 1996;83:1174–1185
  3. Wei WQ, Abnet CC, Lu N, et al. Risk factors for oesophageal squamous dysplasia in adult inhabitants of a high risk region of China. Gut. 2005;54:759–763
  4. Dawsey SM, Fleischer DE, Wang GQ, et al. Mucosal iodine staining improves endoscopic visualization of squamous dysplasia and squamous cell carcinoma of the esophagus in Linxian, China. Cancer. 1998;83:220–231
  5. Shimizu Y, Omori T, Yokoyama A, et al. Endoscopic diagnosis of early squamous neoplasia of the esophagus with iodine staining: high-grade intra-epithelial neoplasia turns pink within a few minutes. J Gastroenterol Hepatol. 2008;23:546–550
  6. Liu H, Li YQ, Yu T, et al. Confocal endomicroscopy for in vivo detection of microvascular architecture in normal and malignant lesions of upper gastrointestinal tract. J Gastroenterol Hepatol. 2008;23:56–61
  7. Gabbert H, Shimoda T, Hainaut P, et al. Squamous cell carcinoma of the oesophagus. Lyon: IARC Press; 2000;
  8. Farhadi M, Tahmasebi Z, Merat S, Kamangar F, Nasrollahzadeh D, Malekzadeh R. Human papillomavirus in squamous cell carcinoma of esophagus in a high-risk population. World J Gastroenterol. 2005;11:1200–1203
  9. Contu SS, Contu PC, Damin DC, et al. pRB expression in esophageal mucosa of individuals at high risk for squamous cell carcinoma of the esophagus. World J Gastroenterol. 2007;13:1728–1731
  10. Parenti AR, Rugge M, Frizzera E, et al. p53 overexpression in the multistep process of esophageal carcinogenesis. Am J Surg Pathol. 1995;19:1418–1422
  11. Wang GQ, Abnet CC, Shen Q, et al. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. Gut. 2005;54:187–192
  12. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97:142–146
  13. Sampliner RE. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett’s esophagus. Am J Gastroenterol. 2002;97:1888–1895
  14. Rex DK, Cummings OW, Shaw M, et al. Screening for Barrett’s esophagus in colonoscopy patients with and without heartburn. Gastroenterology. 2003;125:1670–1677
  15. Weston AP, Sharma P, Mathur S, et al. Risk stratification of Barrett’s esophagus: updated prospective multivariate analysis. Am J Gastroenterol. 2004;99:1657–1666
  16. Menke-Pluymers MB, Hop WC, Dees J, van Blankenstein M, Tilanus HW. Risk factors for the development of an adenocarcinoma in columnar-lined (Barrett) esophagus. The Rotterdam Esophageal Tumor Study Group. Cancer. 1993;72:1155–1158
  17. Buttar NS, Wang KK, Sebo TJ, et al. Extent of high-grade dysplasia in Barrett’s esophagus correlates with risk of adenocarcinoma. Gastroenterology. 2001;120:1630–1639
  18. Iftikhar SY, James PD, Steele RJ, Hardcastle JD, Atkinson M. Length of Barrett’s oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut. 1992;33:1155–1158
  19. Srivastava A, Hornick JL, Li X, et al. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett’s esophagus. Am J Gastroenterol. 2007;102:483–493quiz 694
  20. Galipeau PC, Li X, Blount PL, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. 2007;4:e67
  21. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett’s esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol. 2001;96:2839–2848
  22. Rugge M, Correa P, Dixon MF, et al. Gastric dysplasia: the Padova international classification. Am J Surg Pathol. 2000;24:167–176
  23. Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut. 2000;47:251–255
  24. Montgomery E, Bronner MP, Greenson JK, et al. Are ulcers a marker for invasive carcinoma in Barrett’s esophagus? Data from a diagnostic variability study with clinical follow-up. Am J Gastroenterol. 2002;97:27–31
  25. Hoffman A, Kiesslich R, Bender A, et al. Acetic acid-guided biopsies after magnifying endoscopy compared with random biopsies in the detection of Barrett’s esophagus: a prospective randomized trial with crossover design. Gastrointest Endosc. 2006;64:1–8
  26. Sharma P, Marcon N, Wani S, et al. Non-biopsy detection of intestinal metaplasia and dysplasia in Barrett’s esophagus: a prospective multicenter study. Endoscopy. 2006;38:1206–1212
  27. Anagnostopoulos GK, Yao K, Kaye P, Hawkey CJ, Ragunath K. Novel endoscopic observation in Barrett’s oesophagus using high resolution magnification endoscopy and narrow band imaging. Aliment Pharmacol Ther. 2007;26:501–507
  28. Oberg S, Johansson J, Wenner J, et al. Endoscopic surveillance of columnar-lined esophagus: frequency of intestinal metaplasia detection and impact of antireflux surgery. Ann Surg. 2001;234:619–626
  29. Chen YY, Wang HH, Antonioli DA, et al. Significance of acid-mucin-positive nongoblet columnar cells in the distal esophagus and gastroesophageal junction. Hum Pathol. 1999;30:1488–1495
  30. Chaves P, Cardoso P, de Almeida JC, Pereira AD, Leitao CN, Soares J. Non-goblet cell population of Barrett’s esophagus: an immunohistochemical demonstration of intestinal differentiation. Hum Pathol. 1999;30:1291–1295
  31. DeMeester SR, Wickramasinghe KS, Lord RV, et al. Cytokeratin and DAS-1 immunostaining reveal similarities among cardiac mucosa, CIM, and Barrett’s esophagus. Am J Gastroenterol. 2002;97:2514–2523
  32. Glickman JN, Chen YY, Wang HH, Antonioli DA, Odze RD. Phenotypic characteristics of a distinctive multilayered epithelium suggests that it is a precursor in the development of Barrett’s esophagus. Am J Surg Pathol. 2001;25:569–578
  33. Lomo LC, Blount PL, Sanchez CA, et al. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett’s esophagus cohort. Am J Surg Pathol. 2006;30:423–435
  34. Yu C, Zhang X, Huang Q, Klein M, Goyal RK. High-fidelity DNA histograms in neoplastic progression in Barrett’s esophagus. Lab Invest. 2007;87:466–472
  35. Chao DL, Maley CC, Wu X, et al. Mutagen sensitivity and neoplastic progression in patients with Barrett’s esophagus: a prospective analysis. Cancer Epidemiol Biomarkers Prev. 2006;15:1935–1940
  36. Vaninetti NM, Geldenhuys L, Porter GA, et al. Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett’s esophagus and esophageal adenocarcinoma. Mol Carcinog. 2008;47:275–285
  37. Galipeau PC, Prevo LJ, Sanchez CA, Longton GM, Reid BJ. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett’s) tissue. J Natl Cancer Inst. 1999;91:2087–2095
  38. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett’s esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol. 2000;95:1669–1676
  39. Skacel M, Petras RE, Gramlich TL, Sigel JE, Richter JE, Goldblum JR. The diagnosis of low-grade dysplasia in Barrett’s esophagus and its implications for disease progression. Am J Gastroenterol. 2000;95:3383–3387
  40. Schnell TG, Sontag SJ, Chejfec G, et al. Long-term nonsurgical management of Barrett’s esophagus with high-grade dysplasia. Gastroenterology. 2001;120:1607–1619
  41. Ackroyd R, Tam W, Schoeman M, Devitt PG, Watson DI. Prospective randomized controlled trial of argon plasma coagulation ablation vs. endoscopic surveillance of patients with Barrett’s esophagus after antireflux surgery. Gastrointest Endosc. 2004;59:1–7
  42. Barr H, Shepherd NA, Dix A, Roberts DJ, Tan WC, Krasner N. Eradication of high-grade dysplasia in columnar-lined (Barrett’s) oesophagus by photodynamic therapy with endogenously generated protoporphyrin IX. Lancet. 1996;348:584–585
  43. Ell C, May A, Pech O, et al. Curative endoscopic resection of early esophageal adenocarcinomas (Barrett’s cancer). Gastrointest Endosc. 2007;65:3–10
  44. Prasad GA, Wang KK, Buttar NS, et al. Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett’s esophagus. Gastroenterology. 2007;132:1226–1233
  45. de Vries AC, Haringsma J, Kuipers EJ. The detection, surveillance and treatment of premalignant gastric lesions related to Helicobacter pylori infection. Helicobacter. 2007;12:1–15
  46. Rad R, Prinz C, Neu B, et al. Synergistic effect of Helicobacter pylori virulence factors and interleukin-1 polymorphisms for the development of severe histological changes in the gastric mucosa. J Infect Dis. 2003;188:272–281
  47. Garcia-Gonzalez MA, Lanas A, Quintero E, et al. Gastric cancer susceptibility is not linked to pro- and anti-inflammatory cytokine gene polymorphisms in whites: a Nationwide Multicenter Study in Spain. Am J Gastroenterol. 2007;102:1878–1892
  48. Machado JC, Pharoah P, Sousa S, et al. Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma. Gastroenterology. 2001;121:823–829
  49. Schenk BE, Kuipers EJ, Nelis GF, et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut. 2000;46:615–621
  50. Jakszyn P, Bingham S, Pera G, et al. Endogenous versus exogenous exposure to N-nitroso compounds and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study. Carcinogenesis. 2006;27:1497–1501
  51. Forman D, Newell DG, Fullerton F, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ. 1991;302:1302–1305
  52. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127–1131
  53. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–789
  54. Lauwers GY, Srivastava A. Gastric preneoplastic lesions and epithelial dysplasia. Gastroenterol Clin North Am. 2007;36:813–829
  55. Vaananen H, Vauhkonen M, Helske T, et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol. 2003;15:885–891
  56. Cassaro M, Rugge M, Gutierrez O, Leandro G, Graham DY, Genta RM. Topographic patterns of intestinal metaplasia and gastric cancer. Am J Gastroenterol. 2000;95:1431–1438
  57. Anagnostopoulos GK, Ragunath K, Fortun PJ, Yao K. Identifying Helicobacter pylori-associated gastritis, gastric atrophy and intestinal metaplasia with magnification endoscopy and adaptive index of haemoglobin enhancement technique. Dig Liver Dis. 2005;37:980–981author reply 982
  58. Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, et al. Magnification chromoendoscopy for the diagnosis of gastric intestinal metaplasia and dysplasia. Gastrointest Endosc. 2003;57:498–504
  59. Nakayoshi T, Tajiri H, Matsuda K, Kaise M, Ikegami M, Sasaki H. Magnifying endoscopy combined with narrow band imaging system for early gastric cancer: correlation of vascular pattern with histopathology (including video). Endoscopy. 2004;36:1080–1084
  60. Bodger K, Campbell F, Rhodes JM. Detection of sulfated glycoproteins in intestinal metaplasia: a comparison of traditional mucin staining with immunohistochemistry for the sulfo-Lewis(a) carbohydrate epitope. J Clin Pathol. 2003;56:703–708
  61. Wu MS, Shun CT, Lee WC, et al. Gastric cancer risk in relation to Helicobacter pylori infection and subtypes of intestinal metaplasia. Br J Cancer. 1998;78:125–128
  62. Carneiro F, Huntsman DG, Smyrk TC, et al. Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol. 2004;203:681–687
  63. Morgan C, Jenkins GJ, Ashton T, et al. Detection of p53 mutations in precancerous gastric tissue. Br J Cancer. 2003;89:1314–1319
  64. Leung WK, Kim JJ, Kim JG, Graham DY, Sepulveda AR. Microsatellite instability in gastric intestinal metaplasia in patients with and without gastric cancer. Am J Pathol. 2000;156:537–543
  65. Abraham SC, Park SJ, Lee JH, Mugartegui L, Wu TT. Genetic alterations in gastric adenomas of intestinal and foveolar phenotypes. Mod Pathol. 2003;16:786–795
  66. Rugge M, Cassaro M, Di Mario F, et al. The long term outcome of gastric non-invasive neoplasia. Gut. 2003;52:1111–1116
  67. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20:1161–1181
  68. Everett SM, Axon AT. Early gastric cancer in Europe. Gut. 1997;41:142–150
  69. Greene FL. Management of gastric remnant carcinoma based on the results of a 15-year endoscopic screening program. Ann Surg. 1996;223:701–706discussion 706–708
  70. Abraham SC, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT. Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations. Am J Pathol. 2000;157:747–754
  71. Abraham SC, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT. Sporadic fundic gland polyps: common gastric polyps arising through activating mutations in the beta-catenin gene. Am J Pathol. 2001;158:1005–1010
  72. Abraham SC, Park SJ, Mugartegui L, Hamilton SR, Wu TT. Sporadic fundic gland polyps with epithelial dysplasia: evidence for preferential targeting for mutations in the adenomatous polyposis coli gene. Am J Pathol. 2002;161:1735–1742
  73. Ginsberg GG, Al-Kawas FH, Fleischer DE, Reilly HF, Benjamin SB. Gastric polyps: relationship of size and histology to cancer risk. Am J Gastroenterol. 1996;91:714–717
  74. Hattori T. Morphologic range of hyperplastic polyps and carcinomas arising in hyperplastic polyps of the stomach. J Clin Pathol. 1985;38:622–630
  75. Iida M, Yao T, Itoh H, et al. Natural history of gastric adenomas in patients with familial adenomatosis coli/Gardner’s syndrome. Cancer. 1988;61:605–611
  76. Fishman MJ, Jeejeebhoy KN, Gopinath N, Girotti MJ, Yeung EY, Cullen JB. Small intestinal villous adenoma and celiac disease. Am J Gastroenterol. 1990;85:748–751
  77. Sarre RG, Frost AG, Jagelman DG, Petras RE, Sivak MV, McGannon E. Gastric and duodenal polyps in familial adenomatous polyposis: a prospective study of the nature and prevalence of upper gastrointestinal polyps. Gut. 1987;28:306–314
  78. Solem CA, Harmsen WS, Zinsmeister AR, Loftus EV. Small intestinal adenocarcinoma in Crohn’s disease: a case-control study. Inflamm Bowel Dis. 2004;10:32–35
  79. Tirkes AT, Duerinckx AJ. Adenocarcinoma of the ileum in Crohn disease. Abdom Imaging. 2005;30:671–673
  80. Ouaissi M, Panis Y, Sielezneff I, et al. Long-term outcome after ampullectomy for ampullary lesions associated with familial adenomatous polyposis. Dis Colon Rectum. 2005;48:2192–2196
  81. Bulow S, Bjork J, Christensen IJ, et al. Duodenal adenomatosis in familial adenomatous polyposis. Gut. 2004;53:381–386
  82. Spigelman AD, Owen RW, Hill MJ, Phillips RK. Biliary bile acid profiles in familial adenomatous polyposis. Br J Surg. 1991;78:321–325
  83. Albores-Saavedra J, Henson DE, Klimstra DS. Tumors of the gallbladder, extrahepatic bile ducts, and ampulla of Vater. Armed Forces Institute of Pathology; 2000;
  84. Imai Y, Oda H, Tsurutani N, Nakatsuru Y, Inoue T, Ishikawa T. Frequent somatic mutations of the APC and p53 genes in sporadic ampullary carcinomas. Jpn J Cancer Res. 1997;88:846–854
  85. Park S, Kim SW, Kim SH, Darwish NS, Kim WH. Lack of microsatellite instability in neoplasms of ampulla of Vater. Pathol Int. 2003;53:667–670
  86. Wheeler JM, Warren BF, Mortensen NJ, et al. An insight into the genetic pathway of adenocarcinoma of the small intestine. Gut. 2002;50:218–223
  87. Mizumoto I, Ogawa Y, Niiyama H, et al. Possible role of telomerase activation in the multistep tumor progression of periampullary lesions in patients with familial adenomatous polyposis. Am J Gastroenterol. 2001;96:1261–1265
  88. Saurin JC, Ligneau B, Ponchon T, et al. The influence of mutation site and age on the severity of duodenal polyposis in patients with familial adenomatous polyposis. Gastrointest Endosc. 2002;55:342–347
  89. Arber N, Shapira I, Ratan J, et al. Activation of c-K-ras mutations in human gastrointestinal tumors. Gastroenterology. 2000;118:1045–1050
  90. Norheim Andersen S, Lovig T, Fausa O, Rognum TO. Germline and somatic mutations in exon 15 of the APC gene and K-ras mutations in duodenal adenomas in patients with familial adenomatous polyposis. Scand J Gastroenterol. 1999;34:611–617
  91. Ryan DP, Schapiro RH, Warshaw AL. Villous tumors of the duodenum. Ann Surg. 1986;203:301–306
  92. Lienert A, Bagshaw PF. Treatment of duodenal adenomas with endoscopic argon plasma coagulation. ANZ J Surg. 2007;77:371–373
  93. Perzin KH, Bridge MF. Adenomas of the small intestine: a clinicopathologic review of 51 cases and a study of their relationship to carcinoma. Cancer. 1981;48:799–819
  94. Brien TP, Farraye FA, Odze RD. Gastric dysplasia-like epithelial atypia associated with chemoradiotherapy for esophageal cancer: a clinicopathologic and immunohistochemical study of 15 cases. Mod Pathol. 2001;14:389–396
  95. Doria MI, Doria LK, Faintuch J, Levin B. Gastric mucosal injury after hepatic arterial infusion chemotherapy with floxuridine. A clinical and pathologic study. Cancer. 1994;73:2042–2047
  96. Ormsby AH, Petras RE, Henricks WH, et al. Observer variation in the diagnosis of superficial oesophageal adenocarcinoma. Gut. 2002;51:671–676
  97. Zhu W, Appelman , Henry D, et al. Barrett’s/cardiac high grade dysplasia is not a strong marker for concurrent carcinoma, unless architectural changes suspicious for adenocarcinoma are also present. Lab Invest. 2006;1(Supp. 1):126A

PII: S1756-2317(08)00115-1

doi: 10.1016/j.mpdhp.2008.07.004

Diagnostic Histopathology
Volume 14, Issue 9 , Pages 437-452 , September 2008

Article Tools

* Image Usage & Resolution